The Panel’s Comments
“I typically refrain from commentary, but I will say this: I think this is a phenomenal study, in particular, for one reason,” said FDA panel member Ronald Przygodzki, acting director of Biomedical Laboratory Research and Development at the Department of Veterans Affairs Office of Research & Development.
